SPARCNSESun Pharma Advanced Research Company Limited· PharmaceuticalsMediumNeutral
Announced Thu, 25 Jun · 18:32 IST

SPARC terminates license agreement with CMS Bridging DMCC

Deal CancelledStrategic Transactions View source PDF

SPARC · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+4.5%1-day move
₹224.50
prior close
₹225.00
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-1.5-1.7-0.8+0.3+4.5+6.0+6.5+6.5+17.3+20.3+1.6
Up moveDown movePending
AI summary

SPARC has mutually terminated its November 2019 license agreement with CMS Bridging DMCC, which covered development and commercialization of products Xelpros, Elepsia, Taclantis, PDP-716 and SDN-037 in Mainland China, Hong Kong, Macao and Taiwan. The company states there is no material impact on financials, operations or other activities due to the termination.

Likely market impact

Minimal impact expected. Company confirms no material effect on financials or operations. Loses China region commercialization rights for these products.